A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited. How to better treat patients with unmethylated MGMT is unknown. We performed a trial combining erlotinib and bevacizuma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Raizer, J. J., Giglio, P., Hu, J., Groves, M., Merrell, R., Conrad, C., Phuphanich, S., Puduvalli, V. K., Loghin, M., Paleologos, N., Yuan, Y., Liu, D., Rademaker, A., Yung, W. K., Vaillant, B., Rudnick, J., Chamberlain, M., Vick, N., Grimm, S., Tremont-Lukats, I. W., De Groot, J., Aldape, K., Gilbert, M. R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826294/
https://ncbi.nlm.nih.gov/pubmed/26476729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1958-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados